WCM
UTHR icon

Wedge Capital Management’s United Therapeutics UTHR Stock Holding History

Wedge Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-54,673
Closed -$32.4M – 554
2026
Q1 		$32.4M Sell
54,673
-6,014
-10% -$3M 0.6% 47
2025
Q4 		$29.6M Sell
60,687
-5,865
-9% -$2.73M 0.53% 82
2025
Q3 		$27.9M Sell
66,552
-29,292
-31% -$9.85M 0.47% 78
2025
Q2 		$27.5M Sell
95,844
-11,432
-11% -$3.42M 0.49% 85
2025
Q1 		$33.1M Buy
107,276
+27,829
+35% +$9.54M 0.64% 69
2024
Q4 		$28M Sell
79,447
-10,132
-11% -$3.72M 0.5% 77
2024
Q3 		$32.1M Sell
89,579
-37,230
-29% -$12.6M 0.55% 71
2024
Q2 		$40.4M Sell
126,809
-43,740
-26% -$11.6M 0.72% 53
2024
Q1 		$39.2M Buy
+170,549
New +$38.5M 0.63% 68
2023
Q1 		– Sell
-143,163
Closed -$39.8M – 450
2022
Q4 		$39.8M Sell
143,163
-22,343
-13% -$5.64M 0.64% 32
2022
Q3 		$34.7M Buy
165,506
+5,478
+3% +$1.22M 0.59% 60
2022
Q2 		$37.7M Sell
160,028
-17,635
-10% -$3.59M 0.6% 47
2022
Q1 		$31.9M Buy
177,663
+15,564
+10% +$2.97M 0.43% 106
2021
Q4 		$35M Buy
162,099
+3,864
+2% +$759K 0.43% 89
2021
Q3 		$29.2M Sell
158,235
-25,758
-14% -$5.07M 0.38% 110
2021
Q2 		$33M Sell
183,993
-5,633
-3% -$1.07M 0.4% 72
2021
Q1 		$31.7M Sell
189,626
-9,490
-5% -$1.58M 0.38% 111
2020
Q4 		$30.2M Sell
199,116
-56,611
-22% -$7.43M 0.35% 83
2020
Q3 		$25.8M Sell
255,727
-31,128
-11% -$3.42M 0.35% 114
2020
Q2 		$34.7M Buy
+286,855
New +$32.3M 0.48% 66
2019
Q2 		– Sell
-335,155
Closed -$39.3M – 638
2019
Q1 		$39.3M Buy
335,155
+39,737
+13% +$4.63M 0.45% 77
2018
Q4 		$32.2M Buy
295,418
+25,075
+9% +$2.91M 0.4% 88
2018
Q3 		$34.6M Sell
270,343
-2,990
-1% -$370K 0.33% 96
2018
Q2 		$30.9M Sell
273,333
-47,559
-15% -$5.23M 0.3% 94
2018
Q1 		$36.1M Sell
320,892
-3,739
-1% -$475K 0.35% 81
2017
Q4 		$48M Buy
324,631
+313,143
+2,726% +$39.8M 0.43% 59
2017
Q3 		$1.35M Buy
11,488
+2,059
+22% +$263K 0.01% 322
2017
Q2 		$1.22M Buy
9,429
+1,362
+17% +$170K 0.01% 312
2017
Q1 		$1.09M Buy
8,067
+213
+3% +$32.3K 0.01% 319
2016
Q4 		$1.13M Sell
7,854
-401
-5% -$51.2K 0.01% 320
2016
Q3 		$975K Sell
8,255
-1,235
-13% -$148K 0.01% 329
2016
Q2 		$1M Buy
9,490
+1,774
+23% +$198K 0.01% 316
2016
Q1 		$860K Buy
+7,716
New +$976K 0.01% 336
2014
Q3 		– Sell
-7,125
Closed -$630K – 599
2014
Q2 		$630K Buy
7,125
+3,700
+108% +$356K 0.01% 405
2014
Q1 		$322K Sell
3,425
-150
-4% -$15.3K ﹤0.01% 427
2013
Q4 		$404K Buy
+3,575
New +$322K ﹤0.01% 384

Other funds holding UTHR

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
NI
Nepsis Inc Minneapolis, Minnesota $295M AUM 35.44% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
YCM
Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Wedge Capital Management's UTHR Position: Q2 2026 in Review

Wedge Capital Management sold out of United Therapeutics (UTHR) in Q2 2026, closing a stake of 54,673 shares — an estimated $32.4M sold.

Wedge Capital Management first reported a position in UTHR in Q4 2013 and held it in 36 quarters. The position peaked at $48M in Q4 2017. 83 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Wedge Capital Management reported no remaining United Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Wedge Capital Management sold 54,673 United Therapeutics shares in Q2 2026, an estimated $32.4M.
  • Wedge Capital Management first reported a position in United Therapeutics in Q4 2013 and held it in 36 quarters.
  • Wedge Capital Management's United Therapeutics position peaked at $48M in Q4 2017.
  • 83 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Wedge Capital Management's 13F filing for Q2 2026, filed 10 Jul 2026.